Magnesium Sulphate Injection In Acute Severe Bronchiolitis

Role Of Magnesium Sulphate Injection In Acute Severe Bronchiolitis a Randomized Control Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102239

Enrollment

Registered

2026-01-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders

Interventions

Intervention1: Drug: Intravenous Magnesium Sulphate at a dose of 50 mg/kg, diluted in normal saline and infused over 30 minutes, administered every 8 hours for 24 hours (total of three doses). Contro

Eligibility

Inclusion criteria

Inclusion criteria: Children with Acute Severe Bronchiolitis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluate the efficacy of intravenous magnesium sulphate in reducing respiratory distress, as measured by the Respiratory Distress Assessment Instrument (RDAI), in infants with acute severe bronchiolitis.Timepoint: 2, 6, 12, 24, 48, 72 hours	—

Secondary

Measure	Time frame
Escalation of respiratory support (HFNC, CPAP, intubation), duration of PICU stay, serum magnesium levels, & adverse events.Timepoint: 24,48,72 hours	—

Countries

India

Contacts

Public ContactMIHIR SARKAR

Medical College Kolkata

drmihir09@gmail.com8961616284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026